Bryn Mawr Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $309K | Sell |
5,366
-68
| -1% | -$3.9K | 0.01% | 366 |
|
|
2026
Q1 | $330K | Buy |
5,434
+220
| +4% | +$12.8K | 0.02% | 337 |
|
|
2025
Q4 | $281K | Buy |
5,214
+29
| +0.6% | +$1.4K | 0.01% | 362 |
|
|
2025
Q3 | $234K | Buy |
5,185
+500
| +11% | +$23.4K | 0.01% | 400 |
|
|
2025
Q2 | $217K | Sell |
4,685
-2,969
| -39% | -$146K | 0.01% | 392 |
|
|
2025
Q1 | $467K | Buy |
7,654
+64
| +0.8% | +$3.73K | 0.03% | 264 |
|
|
2024
Q4 | $429K | Buy |
7,590
+318
| +4% | +$17.8K | 0.02% | 293 |
|
|
2024
Q3 | $376K | Hold |
7,272
| – | – | 0.02% | 321 |
|
|
2024
Q2 | $302K | Hold |
7,272
| – | – | 0.02% | 333 |
|
|
2024
Q1 | $394K | Hold |
7,272
| – | – | 0.02% | 311 |
|
|
2023
Q4 | $373K | Sell |
7,272
-3,628
| -33% | -$190K | 0.02% | 308 |
|
|
2023
Q3 | $633K | Buy |
10,900
+4,514
| +71% | +$277K | 0.04% | 254 |
|
|
2023
Q2 | $408K | Buy |
6,386
+2,542
| +66% | +$170K | 0.04% | 221 |
|
|
2023
Q1 | $266K | Sell |
3,844
-109
| -3% | -$7.69K | 0.03% | 240 |
|
|
2022
Q4 | $284K | Buy |
+3,953
| New | +$298K | 0.03% | 235 |
|
|
2021
Q3 | – | Sell |
-3,188
| Closed | -$213K | – | 104 |
|
|
2021
Q2 | $213K | Buy |
+3,188
| New | +$208K | 0.1% | 92 |
|
|
2021
Q1 | – | Sell |
-3,457
| Closed | -$214K | – | 96 |
|
|
2020
Q4 | $214K | Hold |
3,457
| – | – | 0.11% | 89 |
|
|
2020
Q3 | $208K | Sell |
3,457
-295
| -8% | -$17.8K | 0.12% | 82 |
|
|
2020
Q2 | $221K | Hold |
3,752
| – | – | 0.14% | 75 |
|
|
2020
Q1 | $209K | Sell |
3,752
-266
| -7% | -$16.3K | 0.14% | 70 |
|
|
2019
Q4 | $258K | Buy |
+4,018
| New | +$230K | 0.19% | 74 |
|
|
2018
Q4 | – | Sell |
-3,854
| Closed | -$239K | – | 78 |
|
|
2018
Q3 | $239K | Sell |
3,854
-743
| -16% | -$44.1K | 0.2% | 72 |
|
|
2018
Q2 | $254K | Buy |
4,597
+28
| +0.6% | +$1.51K | 0.22% | 65 |
|
|
2018
Q1 | $289K | Sell |
4,569
-1,027
| -18% | -$66.1K | 0.26% | 59 |
|
|
2017
Q4 | $357K | Hold |
5,596
| – | – | 0.47% | 42 |
|
|
2017
Q3 | $357K | Buy |
5,596
+5
| +0.1% | +$292 | 0.37% | 50 |
|
|
2017
Q2 | $312K | Buy |
5,591
+713
| +15% | +$38.8K | 0.35% | 47 |
|
|
2017
Q1 | $265K | Buy |
4,878
+449
| +10% | +$24.6K | 0.27% | 61 |
|
|
2016
Q4 | $259K | Buy |
+4,429
| New | +$242K | 0.26% | 60 |
|
Other funds holding BMY
Bryn Mawr Capital Management's BMY Position: Q2 2026 in Review
Bryn Mawr Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 1.3% in Q2 2026, selling an estimated $3.9K and leaving 5,366 shares worth $309K. The position accounts for 0.01% of the portfolio, ranked #366.
Bryn Mawr Capital Management first reported a position in BMY in Q4 2016 and has held it in 29 quarters since. The position peaked at $633K in Q3 2023. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Bryn Mawr Capital Management held 5,366 shares of Bristol-Myers Squibb worth $309K as of Q2 2026.
- Bryn Mawr Capital Management sold 68 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.9K.
- Bristol-Myers Squibb made up 0.01% of Bryn Mawr Capital Management's portfolio in Q2 2026, its #366 holding.
- Bryn Mawr Capital Management first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 29 quarters since.
- Bryn Mawr Capital Management's Bristol-Myers Squibb position peaked at $633K in Q3 2023.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Bryn Mawr Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.